依达拉奉右莰醇联合复方曲肽在急性缺血性脑卒中患者静脉溶栓后的辅助治疗效果

Adjuvant Therapeutic Effect of Edaravone Dextrocamphorol Combined with Compound Treotide After Intravenous Thrombolysis in Patients with Acute Ischemic Stroke

目的 探讨依达拉奉右莰醇联合复方曲肽在急性缺血性脑卒中(AIS)患者静脉溶栓后的辅助治疗效果。方法 选择2020年7月至2022年9月平顶山市第一人民医院收治的108例AIS患者,依据入院顺序将患者分为单药组和联合组,各54例。两组均接受静脉溶栓治疗,单药组溶栓治疗后接受复方曲肽辅助治疗,联合组溶栓治疗后接受依达拉奉右莰醇联合复方曲肽辅助治疗。治疗14 d后,比较两组临床疗效、神经功能损伤[美国国立卫生研究院卒中评定量表(NIHSS)]、日常生活能力[Barthel指数(BI)]、血液流变学指标[血浆黏度(PSV)、全血高切黏度(HSV)、全血低切黏度(LSV)、纤维蛋白原(FIB)]、炎症因子[血清白细胞介素-1β(IL-1β)、肿瘤坏死因子-α(TNF-α)、转位因子蛋白(TSPO)、Dickkopf同源物1(DKK1)]及随访3个月后预后情况[改良Rankin量表(mRS)评分]。结果 治疗14 d后,联合组临床总有效率高于单药组(P<0.05);与对照组相比,治疗后观察组BI评分较高,NIHSS评分较低(P<0.05);与对照组相比,治疗后观察组PSV、HSV、LSV、FIB、IL-1β、TNF-α、TSPO、DKK1水平降低(P<0.05);随访3个月,观察组mRS评分低于对照组(P<0.05)。结论 依达拉奉右莰醇联合复方曲肽辅助静脉溶栓治疗AIS患者临床效果确切,可改善血液流变学指标,抑制炎症反应,减轻脑损伤,减轻神经功能损伤,提高日常生活能力,改善预后。

Objective To investigate the effect of edaravone dextrocamphorol combined with compound treotide after intravenous thrombolysis in patients with acute ischemic stroke(AIS).Methods A total of 108 AIS patients admitted to the First People’s Hospital of Pingdingshan from July 2020 to September 2022 were selected as the study objects.According to the admission order,the patients were divided into single-drug group and combined group,with 54 cases in each group.The two groups were treated with intravenous thrombolytic therapy.The single-drug group was treated with compound treotide adjuvant therapy after intravenous thrombolytic therapy,and the combined group was treated with edaravone dextrocamphorol adjuvant therapy combined with compound treotide adjuvant therapy after intravenous thrombolytic therapy.After 14 days of treatment,the clinical efficacy,national institutes of health stroke scale(NIHSS)score,Barthel index(BI),hemorheological indexes[plasma viscosity(PSV),whole blood high tangential viscosity(HSV),whole blood low tangential viscosity(LSV),fibrinogen(FIB)],inflammatory factors[interleukin-1β(IL^(-1)β),tumor necrosis factor-α(TNF-α),translocation factor protein(TSPO),Dickkopf homolog 1(DKK1)]and Rankin scale(mRS)scores after 3 months of follow-up were compared between the two groups.Results After 14 days of treatment,the total clinical effective rate of the combination group was higher than that of the single drug group(P<0.05).Compared with the control group,the observation group had higher BI score and lower NIHSS score after treatment(P<0.05).Compared with the control group,the observation group showed a decrease in PSV,HSV,LSV,FIB,IL^(-1)β,TNF-α,TSPO,DKK1 levels after treatment(P<0.05).Following up for 3 months,the mRS score of the observation group was lower than that of the control group(P<0.05).Conclusion The combination of edaravone and camphor combined with compound tripeptide for intravenous thrombolysis in the treatment of AIS patients has a definite clinical effect.It can improve hemorheological indicators,inhibit inflammatory reactions,reduce brain damage,alleviate neurological function damage,improve daily living ability,and improve prognosis.